← Human Trials & Peer-Reviewed Studies
Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity
Plain-language guide to NCT06214468: phase 1 non-randomized trial of NAD+, 26 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06214468
- Phase
- phase 1
- Status
- completed
- Start
- 2024-01-15
- Completion (planned or actual)
- 2025-04-01
- Participants
- 26 (actual)
- Design
- non-randomized, double-blind, diagnostic
- Conditions studied
- Drug Toxicity
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 1 trial, researchers set out to test NAD+.
Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental.
It had two arms (groups): Tylenol and Nicotinamide Riboside (other) and Tylenol Only (active comparator).
The registry classes the interventions as combination product and drug.
More on the Plan
To relieve pain and discomfort, astronauts often use acetaminophen.
Therefore, blood collection from a few volunteers who take acetaminophen, and acetaminophen with NR.
Volunteers are also needed to donate blood.
Who Took Part
Enrollment: 26 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers could join, not only people with the condition.
The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: individual allergic to acetaminophen or nicotinamide riboside.
How the Study Was Run
Design: non-randomized, crossover and double-blind.
Each person switched between NAD+ and the comparison at some point, usually with a gap in between.
Blinding on both sides kept the participants and researchers unaware of who received NAD+.
Those kept unaware of assignments: participant and investigator.
It started in 2024-01-15 with completion listed for 2025-04-01.
It ran at 1 site in United States.
Its stated primary purpose is diagnostic.
What Was Measured
Primary outcome: Count the quantity of NAD(P)(H) present with exposure to acetaminophen, with and without NR. Count the quantity of ox-NAD(P) present with exposure to acetaminophen, with and without NR. Count the quantity of PYR-ribosides present with exposure to acetaminophen, with and without NR.
What This Means in Plain Language
Put simply, this is a phase 1, non-randomized trial of NAD+ in 26 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the NAD+ compound page, all human trials.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.